A Randomized, Double Blind Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of AMG 570 in Subjects With Rheumatoid Arthritis
Phase of Trial: Phase I
Latest Information Update: 11 Sep 2017
At a glance
- Drugs MEDI 0700 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Amgen
- 06 Sep 2017 Status changed from not yet recruiting to recruiting.
- 10 Aug 2017 Planned initiation date changed from 20 Jun 2017 to 15 Aug 2017.
- 18 May 2017 New trial record